Market capitalization | €1.46b |
Enterprise Value | €-1.90b |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | 0.51 |
Cash position | €3.38b |
P/E forward | negative |
P/S forward | 5.18 |
EV/Sales forward | negative |
As a Free StocksGuide user, you can view scores for all 6,875 stocks worldwide.
13 Analysts have issued a Galapagos forecast:
13 Analysts have issued a Galapagos forecast:
Sep '24 |
+/-
%
|
||
Revenue | 60 60 |
50%
50%
|
|
Gross Profit | 60 60 |
48%
48%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -62 -62 |
34%
34%
|
Net Profit | -50 -50 |
295%
295%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Head office | Belgium |
CEO | Paulus Stoffels |
Employees | 1,123 |
Founded | 1999 |
Website | www.glpg.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.